APA (7th ed.) Citation

Manns, M., Poordad, F., Bacon, B., Bruno, S., Esteban, R., Silva, M., . . . Bronowicki, J. (2011). 448 RESPONSE-GUIDED THERAPY WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN REDUCES DURATION IN NAIVE AND PEGINTERFERON ALFA-2B/RIBAVIRIN PREVIOUS-TREATMENT-FAILURE PATIENTS WITH HCV GENOTYPE 1. Journal of Hepatology, 54, S182. https://doi.org/10.1016/S0168-8278(11)60450-9

Chicago Style (17th ed.) Citation

Manns, M.P, et al. "448 RESPONSE-GUIDED THERAPY WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN REDUCES DURATION IN NAIVE AND PEGINTERFERON ALFA-2B/RIBAVIRIN PREVIOUS-TREATMENT-FAILURE PATIENTS WITH HCV GENOTYPE 1." Journal of Hepatology 54 (2011): S182. https://doi.org/10.1016/S0168-8278(11)60450-9.

MLA (9th ed.) Citation

Manns, M.P, et al. "448 RESPONSE-GUIDED THERAPY WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN REDUCES DURATION IN NAIVE AND PEGINTERFERON ALFA-2B/RIBAVIRIN PREVIOUS-TREATMENT-FAILURE PATIENTS WITH HCV GENOTYPE 1." Journal of Hepatology, vol. 54, 2011, p. S182, https://doi.org/10.1016/S0168-8278(11)60450-9.